India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 919.17 billion. The enterprise value is 970.30 billion.
| Market Cap | 919.17B |
| Enterprise Value | 970.30B |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
Mankind Pharma has 412.76 million shares outstanding. The number of shares has increased by 2.35% in one year.
| Current Share Class | 412.76M |
| Shares Outstanding | 412.76M |
| Shares Change (YoY) | +2.35% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 57.72% |
| Owned by Institutions (%) | 19.91% |
| Float | 106.26M |
Valuation Ratios
The trailing PE ratio is 52.31 and the forward PE ratio is 39.38. Mankind Pharma's PEG ratio is 2.32.
| PE Ratio | 52.31 |
| Forward PE | 39.38 |
| PS Ratio | 6.79 |
| PB Ratio | 5.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 39.07 |
| P/OCF Ratio | 31.99 |
| PEG Ratio | 2.32 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.84, with an EV/FCF ratio of 41.24.
| EV / Earnings | 55.42 |
| EV / Sales | 7.16 |
| EV / EBITDA | 29.84 |
| EV / EBIT | 39.92 |
| EV / FCF | 41.24 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.14 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 2.58 |
| Debt / FCF | 3.56 |
| Interest Coverage | 3.25 |
Financial Efficiency
Return on equity (ROE) is 13.46% and return on invested capital (ROIC) is 8.60%.
| Return on Equity (ROE) | 13.46% |
| Return on Assets (ROA) | 7.07% |
| Return on Invested Capital (ROIC) | 8.60% |
| Return on Capital Employed (ROCE) | 11.14% |
| Revenue Per Employee | 5.02M |
| Profits Per Employee | 648,984 |
| Employee Count | 26,978 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, Mankind Pharma has paid 3.97 billion in taxes.
| Income Tax | 3.97B |
| Effective Tax Rate | 18.29% |
Stock Price Statistics
The stock price has decreased by -13.50% in the last 52 weeks. The beta is 0.22, so Mankind Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -13.50% |
| 50-Day Moving Average | 2,457.84 |
| 200-Day Moving Average | 2,447.80 |
| Relative Strength Index (RSI) | 31.45 |
| Average Volume (20 Days) | 455,699 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 135.46 billion and earned 17.51 billion in profits. Earnings per share was 42.63.
| Revenue | 135.46B |
| Gross Profit | 94.52B |
| Operating Income | 24.19B |
| Pretax Income | 21.68B |
| Net Income | 17.51B |
| EBITDA | 32.29B |
| EBIT | 24.19B |
| Earnings Per Share (EPS) | 42.63 |
Balance Sheet
The company has 34.99 billion in cash and 83.69 billion in debt, giving a net cash position of -48.70 billion or -117.99 per share.
| Cash & Cash Equivalents | 34.99B |
| Total Debt | 83.69B |
| Net Cash | -48.70B |
| Net Cash Per Share | -117.99 |
| Equity (Book Value) | 155.29B |
| Book Value Per Share | 370.26 |
| Working Capital | 10.15B |
Cash Flow
In the last 12 months, operating cash flow was 28.74 billion and capital expenditures -5.21 billion, giving a free cash flow of 23.53 billion.
| Operating Cash Flow | 28.74B |
| Capital Expenditures | -5.21B |
| Free Cash Flow | 23.53B |
| FCF Per Share | 57.00 |
Margins
Gross margin is 69.78%, with operating and profit margins of 17.86% and 12.93%.
| Gross Margin | 69.78% |
| Operating Margin | 17.86% |
| Pretax Margin | 16.01% |
| Profit Margin | 12.93% |
| EBITDA Margin | 23.84% |
| EBIT Margin | 17.86% |
| FCF Margin | 17.37% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.36% |
| Buyback Yield | -2.35% |
| Shareholder Yield | -2.26% |
| Earnings Yield | 1.90% |
| FCF Yield | 2.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |